BIA Signs Concordat on Openness on the Use of Animals in Research
News May 14, 2014
The BioIndustry Association (BIA) is one of over 70 organisations - including charities, research funders and industry organisations - signed up to the Concordat on Openness on Animal Research, launched today. Signatories to the Concordat have agreed to four central commitments pledging greater openness and transparency about the use of animals in scientific, medical and veterinary research in the UK.
The goal of the Concordat is to ensure the public is able make a more informed judgement about the use of animals in research, by ensuring they have accurate, up-to-date information about what animal research involves, the role it plays in scientific discovery and treatment development, how it is regulated, and what researchers and animal care staff do to promote animal care and welfare, reduce animal usage and minimise suffering and harm to animals.
Steve Bates, BIA Chief Executive Officer, commented:
"Animal research is key to scientific discovery and medical progress, and will remain so until there are alternatives. The use of animals in research is strictly regulated and industry has long been committed to ensuring high standards of animal welfare and replacing, refining and reducing the use of animals where possible.
"Animal research is an underpinning and essential part of developing life-saving and life-changing therapies, and this is why we are happy to be part of a coalition which explains its importance to the British public. Public support for animal research remains strong and this Concordat will help to maintain it.
"Whilst the BIA is not directly involved in scientific research, many of our members necessarily use animals either directly or through CROs as part of the research and development of ground-breaking technologies and therapies for patients. We will be open and pro-active in communicating about why industry conducts animal research, its benefits and limitations. We encourage our members to be aware of the Concordat, and will support any members to be open about animal research in our sector."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019